Press release
Pre-Eclampsia Pipeline Assessment, 2024 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin
"Pre-Eclampsia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pre-Eclampsia Market.
The Pre-Eclampsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Pre-Eclampsia Pipeline Report: https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pre-Eclampsia treatment therapies with a considerable amount of success over the years.
• Pre-Eclampsia companies working in the treatment market are Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin, and others, are developing therapies for the Pre-Eclampsia treatment
• Emerging Pre-Eclampsia therapies in the different phases of clinical trials are- GMA-312, C 103, CBP-4888, KW-3357, and others are expected to have a significant impact on the Pre-Eclampsia market in the coming years.
• In January 2024, Comanche Biopharma, headquartered in the United States, has successfully completed an oversubscribed Series B financing round, securing $75 million. The funding will be utilized to advance the development of its small interfering RNA (siRNA) therapy, CBP-4888, intended for the treatment of preeclampsia. Notable investors in this round include Google Ventures, F-Prime Capital, Lilly Asia Ventures, Longview Healthcare Ventures, New Enterprise Associates (NEA), and Atlas Venture. Additionally, Scott Gottlieb from NEA and David Grayzel from Atlas will be joining Comanche's board, bringing valuable expertise and guidance to the company's strategic direction.
• KW-3357 is an antithrombin (AT) medication developed using recombinant DNA technology and precise control over sugar-chain composition. It is a recombinant AT formulation designed to possess an identical amino acid sequence and sugar chain structure as natural human AT.
Pre-Eclampsia Overview
Pre-eclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most commonly the liver and kidneys. It typically occurs after the 20th week of pregnancy and can affect both the mother and the unborn baby.
Get a Free Sample PDF Report to know more about Pre-Eclampsia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Pre-Eclampsia Drugs Under Different Phases of Clinical Development Include:
• GMA-312: Gmax Biopharm
• C 103: Vicore Pharma
• CBP-4888: Comanche Biopharma
• KW-3357: Kyowa Kirin
Pre-Eclampsia Route of Administration
Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Pre-Eclampsia Molecule Type
Pre-Eclampsia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Pre-Eclampsia Pipeline Therapeutics Assessment
• Pre-Eclampsia Assessment by Product Type
• Pre-Eclampsia By Stage and Product Type
• Pre-Eclampsia Assessment by Route of Administration
• Pre-Eclampsia By Stage and Route of Administration
• Pre-Eclampsia Assessment by Molecule Type
• Pre-Eclampsia by Stage and Molecule Type
DelveInsight's Pre-Eclampsia Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Pre-Eclampsia product details are provided in the report. Download the Pre-Eclampsia pipeline report to learn more about the emerging Pre-Eclampsia therapies
https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Pre-Eclampsia Therapeutics Market include:
Key companies developing therapies for Pre-Eclampsia are - Kyowa Kirin, Gmax Biopharm, Vicore Pharma, and others.
Pre-Eclampsia Pipeline Analysis:
The Pre-Eclampsia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pre-Eclampsia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pre-Eclampsia Treatment.
• Pre-Eclampsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pre-Eclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pre-Eclampsia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pre-Eclampsia drugs and therapies
https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pre-Eclampsia Pipeline Market Drivers
• Increasing women population suffering from Pre-Eclampsia, growing focus on the development of innovative Pre-Eclampsia diagnostic products are some of the important factors that are fueling the Pre-Eclampsia Market.
Pre-Eclampsia Pipeline Market Barriers
• However, high cost associated with the treatment of Pre-Eclampsia, lack of awareness among patients regarding the disease and other factors are creating obstacles in the Pre-Eclampsia Market growth.
Scope of Pre-Eclampsia Pipeline Drug Insight
• Coverage: Global
• Key Pre-Eclampsia Companies: Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin, and others
• Key Pre-Eclampsia Therapies: GMA-312, C 103, CBP-4888, KW-3357, and others
• Pre-Eclampsia Therapeutic Assessment: Pre-Eclampsia current marketed and Pre-Eclampsia emerging therapies
• Pre-Eclampsia Market Dynamics: Pre-Eclampsia market drivers and Pre-Eclampsia market barriers
Request for Sample PDF Report for Pre-Eclampsia Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Pre-Eclampsia Report Introduction
2. Pre-Eclampsia Executive Summary
3. Pre-Eclampsia Overview
4. Pre-Eclampsia- Analytical Perspective In-depth Commercial Assessment
5. Pre-Eclampsia Pipeline Therapeutics
6. Pre-Eclampsia Late Stage Products (Phase II/III)
7. Pre-Eclampsia Mid Stage Products (Phase II)
8. Pre-Eclampsia Early Stage Products (Phase I)
9. Pre-Eclampsia Preclinical Stage Products
10. Pre-Eclampsia Therapeutics Assessment
11. Pre-Eclampsia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pre-Eclampsia Key Companies
14. Pre-Eclampsia Key Products
15. Pre-Eclampsia Unmet Needs
16 . Pre-Eclampsia Market Drivers and Barriers
17. Pre-Eclampsia Future Perspectives and Conclusion
18. Pre-Eclampsia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Pre-Eclampsia Market https://www.delveinsight.com/report-store/preeclampsia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pre-Eclampsia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Pre-Eclampsia Epidemiology https://www.delveinsight.com/report-store/pre-eclampsia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pre-Eclampsia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pre-Eclampsia Pipeline Assessment, 2024 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin here
News-ID: 3491491 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region.
The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,…
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies
DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with…
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers.
The global…
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market.
The CD40 Pipeline report embraces in-depth commercial and…
More Releases for Insight
Europe Predictive Maintenance Market, Segmentation, Insight, Scope, & Insight by …
Europe Predictive Maintenance Market will project a CAGR of 40.10% during the forecast up to 2029.
Predictive maintenance is known to lead a huge increase in ROI. It can decline maintenance costs up to 25%-30%, decrease breakdowns to 70%-75%, and reduce downtime to 35%-45%. These services are being highly deployed as they save overall cost for enterprises.
Europe Predictive Maintenance Market was valued at USD 490.88 million in 2021 and is expected…
Returnable Transport Packaging Market, Segmentation, Insight, Scope, & Insight b …
Returnable Transport Packaging Market grows at a CAGR of 5.9% in the forecast period 2021-2028.
Market Analysis & Insights: Returnable Transport Packaging Market
Returnable transport packaging market will grow at a rate of 5.9% for the forecast period of 2021 to 2028. Rising reduction in cost of supply chain cycle and reduction of operational cost which acts as an essential factor driving the returnable transport packaging market.
Traditional methods of packaging that…
Next-Generation Firewall Market, Segmentation, Insight, Scope, & Insight by 2028 …
Next-Generation Firewall Market grows at a CAGR of 11.9% in the forecast period 2021-2028.
Market Analysis & Insights: Next-Generation Firewall Market
The next-generation firewall market is expected to witness market growth at a rate of 11.9% in the forecast period of 2021 to 2028. Data Bridge Market Research report on next-generation firewall market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing…
System Integration Market, Segmentation, Insight, Scope, & Insight by 2028.
System Integration Market grows at a CAGR of 10.67% in the forecast period 2022-2029.
System Integration Market Share Analysis
Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to…
Crypto Asset Management Market, Segmentation, Insight, Scope, & Insight by 2029.
Crypto Asset Management Market grows at a CAGR of 25.50% in the forecast period 2022-2029.
Market Analysis & Size: Crypto Asset Management Market
Cryptocurrency is one of the more exciting investing prospects to emerge in recent years. An increasing number of institutional investors and wealth managers who have never invested in cryptocurrencies are getting ready to do so in the upcoming year as their prices continue to rise. The global market…
Optical Waveguide Display Market, Segmentation, Insight, Scope, & Insight by 202 …
Optical Waveguide Display Market grows at a CAGR of 12.90% in the forecast period 2022-2029.
Market Analysis & Insights: Optical Waveguide Display Market
Augmented reality (AR) portable and wearable devices have emerged as one of the greatest technology in past few years. Optical waveguide technology has the best potential to enable the consumer-grade AR glasses owing to its appearance, mass production capability and optical performance. It is being considered an unparalleled choice…
